Skip to main content

Table 3 Subgroup analysis for outcomes (displayed with RR or SMD)

From: High-flow nasal cannula oxygen therapy versus conventional oxygen therapy in patients after planned extubation: a systematic review and meta-analysis

Outcomes Postextubation respiratory failure
(RR)
Reintubation
(RR)
Respiratory rate
(SMD)
PaO2
(SMD)
Subgroup analyses
Study type
 RCT study 0.61 (0.41, 0.92) 0.58 (0.30, 1.11) − 1.12 (− 1.45, − 0.79) 0.39 (− 0.02,0.79)
 Crossover study Na Na − 0.35 (− 0.75, 0.04) 0.14 (− 0.23, 0.51)
Interaction Na Na P = 0.004 P = 0.38
Severity of patients
 Severe populations 0.42 (0.12, 1.52) 0.39 (0.13, 1.19) − 0.56 (− 1.29, 0.18) 0.31 (0.05, 0.58)
 Non severe population 0.72 (0.53, 0.99) 0.81 (0.27, 2.45) − 0.93 (− 1.36, − 0.50) 0.35 (− 0.29, 1.00)
Interaction 0.42 0.36 0.39 0.92
HFNC flow
 ≥ 40 L/min 0.59 (0.34, 1.05) 0.72 (0.29, 1.83) − 1.14 (− 1.47, − 0.81) 0.39 (− 0.02, 0.79)
 < 40 L/min 0.58 (0.35, 0.95) 0.39 (0.21, 0.72) − 0.44 (− 1.09, 0.21) 0.10 (− 0.33, 0.52)
Interaction 0.94 0.28 0.06 0.33
Non-hypercapnic or not
 Non-hypercapnic 0.65 (0.44, 0.94) 0.52 (0.29, 0.93) − 0.16 (− 0.59, 0.26) 0.10 (− 0.33, 0.52)
 Mixeda 0.48 (0.18, 1.29) 0.45 (0.12, 1.77) − 1.07 (− 1.37, − 0.77) 0.39 (− 0.02, 0.79)
 Interaction 0.59 0.86 0.0007 0.33
HFNC duration
 ≥ 24 h 0.52 (0.33, 0.84) 0.48 (0.26, 0.89) − 1.12 (− 1.45, − 0.79) 0.58 (0.27, 0.90)
 < 24 h 0.88 (0.58, 1.34) 0.88 (0.11, 7.33) − 0.35 (− 0.75, 0.04) 0.09 (− 0.13, 0.30)
Interaction P = 0.10 P = 0.59 P = 0.004 P = 0.01
Post cardiac surgery or not
 Post cardiac surgery Na 0.96 (0.04, 24.84) Na Na
 Other patients 0.62 (0.42, 0.92) 0.55 (0.28, 1.08) − 0.70 (− 1.16, − 0.25) 0.30 (0.04, 0.56)
Interaction Na P = 0.74 Na Na
  1. RRs and 95% confidence intervals (CIs) were calculated for the binary data, and the standardized mean differences (SMDs) and 95% CIs were calculated for the continuous data variables
  2. RR risk ratio, SMD standardized mean difference, RCT randomized controlled trial, HFNC high-flow nasal cannula, PaO2 partial pressure of arterial oxygen
  3. aMeans studies included patients with hypoxemic or/and hypercapnic respiratory failure